Jointechlabs Adds Orthopedic and Aesthetic Depth to Scientific Advisory Board

Renowned doctors Dr. William D. Murrell (orthopedics) and Dr. Carlos Mercado (aesthetics) bring new scientific and market savvy to the company

Brandon, FL – April 24, 2024 – Jointechlabs, Inc., a Florida-based regenerative medicine devices and therapeutics company, today announced the addition of two prominent physicians and researchers to the company’s scientific advisory board. New members include Dr. William D. Murrell and Dr. Carlos Mercado, who join existing board members Dr. Mitchell Sheinkop, Dr. Ron Arbel, Dr. Elizaveta Kon, and Dr. Susan Chubinskaya.

Dr. William Murrell

Dr. William D. Murrell is a renowned Orthopedic Surgeon specializing in Sports Medicine and Orthopedic Surgery of the shoulder, elbow, and knee. Also an educator and researcher, he is an attending Orthopedic Surgeon at Harlem Hospital Center, New York. Formerly he held the same position at Gardner Orthopedics in Florida. He is the former President of the American Musculoskeletal Wellness Institute and Director of a Sports Medicine Center in Dubai.

Dr. Murrell is the Principal Investigator in clinical trials investigating adjuvant stem cells in treating articular cartilage defect(s). He has authored several publications and book chapters on Musculoskeletal Medicine and Biological Treatments. Dr. Murrell is the Co-Founder and Co-Editor-in-Chief of the Biologic Orthopaedic Journal. Additionally, he is Associate Editor for the Journal Orthopedic Surgery Research and Journal of Clinical Orthopedics and Trauma. He sits on numerous other advisory and editorial boards.

He joins prominent other orthopedic and sports medicine luminaries on the company’s scientific advisory board.

Dr. Carlos Mercado

Dr. Carlos Mercado is a world-renowned cosmetic surgeon. He has designed new procedures that have helped thousands of patients around the world. Dr. Mercado is the inventor of the Colombian Butt Lift, Colombian Liposculpture, and Erectus Shots, as well as one of the pioneers of using regenerative medicine for cosmetic procedures. He has traveled around the world training other surgeons on his techniques that have offered better outcomes than traditional procedures for the same conditions.

Dr. Mercado is a member of the American Medical Association, American Academy of Cosmetic Surgery, and American Academy of Liposuction Surgery. He is a fellow of the American Academy of Anti-Aging, and is board certified in family medicine and geriatrics. His success has also been recognized by patients: he was rated Doctor of the Year at Florida hospitals for three years running and was one of the top physicians in America in 2018. Dr. Mercado’s Eterna MD clinic has proven to be one of the most innovative and successful cosmetic surgery practices.

Dr. Mercado’s research and medical understanding brings a new dimension on aesthetic and cosmetic uses for microfat to the board and to Jointechlabs.

“As a physician and researcher, I have the highest regard for Dr. Murrell and Dr. Mercado, and I am excited that they have joined our scientific advisory board,” said Dr. Nathan Katz, CEO of Jointechlabs.

The Scientific Advisory Board

These two distinguished individuals join a board that includes:

Dr. Mitchell Sheinkop. Dr. Sheinkop is a Board-Certified Orthopedic Surgeon and a former director of the joint replacement program and Professor Emeritus at Rush University Medical Center. He is a leading authority on the treatment of patients with complex hip and knee disorders. Professor Sheinkop is well known for his pioneering use of computer-assisted navigation, minimally-invasive technologies and hip resurfacing techniques.

Dr. Ron Arbel: Dr. Arbel is an orthopedic surgeon and a leading Israeli specialist in sports medicine. Dr. Arbel was named one of Israel’s best physicians according to Forbes magazine. He heads the Knee Replacement Department at the lchilov Hospital.

Dr. Elizaveta Kon. Dr. Elizaveta Kon is the current President of the International Cartilage Regeneration and Joint Preservation Society (ICRS). She is also an Associate Professor of Orthopaedic Surgery at Humanitas University, Milan, Italy. Professor Kon is the holder of several other appointments.
She is a principal investigator of numerous research projects and clinical trials regarding biotechnology applications in orthopedics.

Dr. Susan Chubinskaya: Susan Chubinskaya, PhD, is a tenured Professor in the Department of Orthopaedic Surgery and Rehabilitation and Vice President and Executive Vice Provost for Faculty Affairs at the University of Texas Medical Branch. She is an internationally recognized authority in the field of cartilage repair/regeneration, especially in post-traumatic and degenerative osteoarthritis.

About Jointechlabs

Privately-held Jointechlabs is an emerging worldwide leader in point-of-care regenerative medicine. Jointechlabs enables healthcare practitioners and hospitals to provide safe, cost-effective, non-surgical regenerative medicine therapies at the point-of-care without change in infrastructure.


FDA-cleared MiniTC® for the US market is a stand-alone device for processing autologous fat into regenerative-cell-rich microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-pending Mini-Stem System® prepares microfat and also extracts Stromal Vascular Fraction.


Pipeline products include stem-cell therapeutics such as 3D Bioprinted wound repair and injectable stem cell scaffolds.


More information at www.jointechlabs.com

When BMAC (Bone Marrow) Isn’t Indicated, Microfat May Be!

Microfat (MFAT) has many advantages over Bone Marrow Aspirate Concentrate and can usually be tolerated in cases when BMAC cannot.

Image of bone marrow on left and adipose cells on right.

BMAC and MFAT have a lot in common in orthopedics. They both can provide pain relief in joints, both are autologous, both less invasive and less costly alternatives to surgery, both are orthobiologic, both have very low risk of infection or rejection, both can often be performed in clinic rather than procedure rooms or hospitals, and both have legions of loyal doctor users and satisfied patients. Perhaps you are one of them.

They work differently but both contain mesenchymal stem cells (MSCs) that we believe can restore, revitalize, and regenerate injured or damaged tissue. Since BMAC has been in use longer than MFAT, many doctors who use BMAC haven’t considered MFAT, either because they believe BMAC is superior or they just don’t know enough about MFAT.

Microfat Advantages

Generally, MFAT has some significant advantages over BMAC, including:

  • MFAT contains many more MSCs than does BMAC, and MSCs are considered a primary regenerative component to regenerative medicine treatments.
  • Stem cells remain numerous in adipose tissue with age while MSCs in BMAC significantly diminish after age 50.
  • Some patients feel that removing belly fat, even a small amount, is a very positive bonus.  Others feel more comfortable losing fat rather than losing bone marrow (even when aware both the fat and the marrow can be replaced).
  • Microfat has cushioning properties that BMAC does not.
  • MFAT MSCs can be easily harvested and the procedure is less invasive and less painful than the one performed to obtain BMAC.
  • In vitro studies demonstrate that MFAT MSCs maintain their phenotype for a longer period and exhibit higher proliferation rates than BMAC.
  • Microfat produced by MiniTC can address up to four joints at the same time for minimal additional expense.
  • See https://sheinkopmd.com/power-of-fat-svf-for-orthopaedic-issue/

Additionally, BMAC cannot be used in certain situations, such as if a patient is on a medication that contraindicates BMAC.

When BMAC is not Indicated

Here are some MFAT traits that BMAC-using physicians should consider when there are issues with BMAC:

  • About the same cost as BMAC kits.
  • May be used for those with systemic diseases such as leukemia and lymphoma after approval by oncologist that disease is in remission.
  • May be used on patients using prescription medications that adversely affect bone marrow.
  • Affective in Kellgren and Lawrence (K/L) 4 OA.
  • May be used within 12 weeks of chemotherapy and irradiation.
  • Not affected by most prescription drugs.
  • May be used with BMI>32.5.
  • For those who have failed BMAC injections.
  • Proving to be very effective in Rotator Cuff Pathology.
  • May used in almost every setting where BMAC not indicated.

MiniTC Microfat Processing Advantages

MiniTC, the industry-leading microfat processing system from Jointechlabs, has advantages over other MFAT systems, including:

  • Highest regenerative cell yield: MiniTC produces the industry’s highest cell yield, leading to superior outcomes.
  • Sterile, disposable, all-in-one: Everything comes in a single box and a sterile, disposable process that simplifies procedures.
  • Highest quantity of microfat in one use.  Can address up to four joints at the same time for minimal additional expense.
  • Quick and consistent results: Pure microfat can be produced in just 30 minutes, and the entire procedure takes under an hour. The standardized protocol eliminates manual shaking and produces consistent results unmatched by other solutions.
  • Injectable with a fine gauge needle. 
  • Fits YOUR workflow. MiniTC can be operated by you or your medical staff right in your office or clinic.
  • Simple. At the end of the day, MiniTC stands out because it’s fast and easy to use.  
  • Competitive price: MiniTC is priced lower than other FDA-cleared alternatives.
  • FDA cleared and made by Jointechlabs, an ISO 13485:2016 certified company.
  • See more at https://Jointechlabs.com/minitc/

Physicians who use BMAC recognize the healing power of orthobiologics. These same physicians owe it to themselves and their patients to consider MFAT and MiniTC.

Jointechlabs’ CEO on “Talk is Biotech”

If you want some insight on Jointechlabs, orthobiologics, and one man’s interesting life journey, check out this interview.

From the podcast description:

“Join us on the Talk is Biotech! podcast as we chat with Nathan Katz about his incredible journey from completing his PhD to becoming a medical scientist and ultimately a successful CEO of Jointechlabs, Inc. Nathan shares his personal story and insights on how he navigated his career path, including tips for other aspiring medical scientists and entrepreneurs. Don’t miss out on this inspiring and informative episode!”

Joint Venture and Patent Grant Mark Jointechlabs’ Entry Into China Regenerative Medicine Microfat Market

China focus includes a joint venture with a top Shanghai/Suzhou-based medical technology company and the granting of a core Chinese patent covering microfat (adipose tissue) processing.

BRANDON, FL, OCT. 2, 2023/PRNewswire. Jointechlabs, Inc., a Regenerative Medicine Solutions company announced that it has been granted a core patent by the China National Intellectual Property Administration covering adipose tissue processing and has entered into a joint venture with Bangyi Medical Technology Co., Ltd. to develop the aesthetic, plastic surgery, and orthopedic-sports medicine market in China.

The China Patent

Jointechlabs’ unique technology is designed to enable health practitioners worldwide to utilize autologous adipose tissue and its derivates (a person’s own fat) for joint pain relief and a wide variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications.


Patent CN115722351A titled “SYSTEM AND METHODS FOR PREPARATION OF ADIPOSE-DERIVED STEM CELLS” has been granted. This patent addresses the core operation and features of MiniTC®, the company’s flagship adipose processing system. The patent covers MiniTC’s technological superiority including industry-leading microfat purity, quantity, and processing speed.


“Innovation and market depth are both key to our success and strategy as a pioneer and leader of the regenerative medicine industry,” said Dr. Nathan Katz, CEO of Jointechlabs. “This patent strengthens our global intellectual property portfolio and allows us to bring our innovations to the Chinese public.”

Jointechlabs has a portfolio of worldwide patents in jurisdictions including China, the United States, EU, Israel, Japan, and Ukraine.

Celebrating the inauguration of Zann Medical

The Partnership

Jointechlabs also announced Zann Medical Technology Co., Ltd., a joint venture agreement with Bangyi Medical Technology Co., Ltd., a leading provider of medical technology solutions in China. With this agreement, Zann Medical will market and distribute Jointechlabs’ regenerative medicine products in China. In this partnership, Jointechlabs will provide licensed technology, training, manufacturing knowhow, and technical support. Correspondingly, Bangyi will market, sell, train, service, and support the licensed products. The Bangyi distribution network includes over 50 representatives and 500 distributors servicing over 600 hospitals and medical practices.


Dr. Nishit Pancholi, COO of Jointechlabs said “Bangyi is the right partner to help us bring our regenerative medicine solutions to China for the benefit of so many aesthetic, plastic surgery, and orthopedic-sports medicine patients. Therefore, we look forward to serving the needs of the Chinese population and the medical community.”


Jerry Luo, Chairman of the Board and co-founder of Bangyi, said “We forecast significant demand for MiniTC and Jointechlabs products throughout China.” Simon Chen, Managing Director and co-founder added “Accordingly we are excited to work with Jointechlabs and together address regenerative medicine needs throughout China.”

About Jointechlabs

Headquartered in Brandon, FL, privately-held Jointechlabs is an emerging worldwide leader in regenerative medicine. The company enables healthcare practitioners to provide safe, cost-effective, non-surgical therapies at the point-of-care without change in infrastructure.


FDA-cleared MiniTC® is a stand-alone device for processing autologous fat into regenerative-cell-rich microfat. Microfat’s uses include a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Additionally, in certain markets, CE-Mark-pending Mini-Stem System® extracts microfat and Stromal Vascular Fraction.


Pipeline includes development of stem-cell based therapeutics with 3D Bioprinted constructs and injectable stem cell scaffolding.

More Information: https://www.jointechlabs.com.

Contact: nishit.pancholi@jointechlabs.com.

#

Best Practices Adipose Presentation for Practitioners

For people new to microfat as well as for experienced clinicians

Dr. Nathan Katz, adipose tissue expert and CEO of Jointechlabs, discusses the scientific basis for the use of adipose tissue and microfat in regenerative medicine and discusses best practices in microfat-based procedures and the processing of microfat for optimal results.

Dr. Nathan Katz, speaker in this best practices presentation.
Dr. Nathan Katz, CEO, Jointechlabs, Inc.

This presentation is designed both for doctors who are new to microfat and/or regenerative medicine and for doctors who use microfat and want to understand best practices.

Read Dr. Katz’s bio here: https://jointechlabs.com/about/

The following is a transcript of the first portion of the best practices presentation:

“Hello, I’m Nathan Katz.

I’m going to talk today about

fat – like you can see on my background screen. I have to disclose

that I’m the CEO of a company that is involved in the

development and manufacturing of products in the field of regenerative

medicine, specifically related to the processing of fat. However,

for this presentation, I will try as much as possible to present the scientific

aspects of adipose tissue and the

application of adipose derived products

in the different regenerative medicine applications.

I hold a PhD in biology

and I have medical background.

You can see that we love your fat. It’s our slogan,

and we literally love the fat because fat is a

very potent and very rich human tissue that

if leveraged properly can be applied for different applications;

pain mitigation, aesthetics and wound healing. And that’s

what we do, what industry does, and the

goal to find the proper way, how to apply fat,

how to process fat properly, and how to learn

to deal with the adipose tissue.”

Jointechlabs Makes Microfat-based Regenerative Medical Procedures More Efficient and Profitable

Faster, simpler, and more efficient microfat-based procedures

BRANDON, FL/September 19, 2023 – Designed to save a physician time when performing any microfat-based medical procedure, Jointechlabs, Inc. has optimized the components and process of its industry-leading MiniTC® Microfat Processing system.  These optimizations produce greater patient and doctor satisfaction, increase profitability, and set a new standard for regenerative medicine efficiency.

A microfat-based procedure consists of three phases: removing (harvesting) fat from a patient, processing that fat into microfat, and injecting the microfat back into the patient.  MiniTC is the efficiency and quality leader for fat processing, yet physicians demand efficiency throughout the entire procedure. Jointechlabs is meeting this demand with components, automation, and best practice optimization in all three phases.

Below are typical times for each of the above phases in a common knee joint pain procedure showing 2023 efficiency improvements over 35%:

 Fat HarvestingMicrofat ProcessingMicrofat ReinjectionProcedure Total
201830 minutes30 minutes20 minutes80 minutes
202315 minutes25 minutes10 minutes50 minutes
MiniTC® and components – optimized for microfat procedure efficiency.

FatLok™ – the only syringe on the market formally designed and intended for lipoaspiration

Dr. Ariana DeMers, Orthopedic Surgeon at Restore Orthobiologic, says “One of my favorite parts of MiniTC is the harvester. It’s probably the best one on the market.”

Optimizing the Process, Not Just the Components

In addition to bespoke component design, the company has standardized and further automated the process at each stage of a MiniTC-based procedure, again reducing the labor needed, simplifying training, allowing doctors to easily gain proficiency and other medical professionals to perform much of the process, and leading to consistent results.

“Our goal is to make microfat-based procedures using MiniTC the simplest and most efficient on the market and to move the regenerative medicine industry forward.  We are striving to assure a stress-free, time-efficient process, from harvesting through processing to effortless injection.” said Dr. Nathan Katz, Jointechlabs CEO. “Henry Ford had a fantastic vehicle engine in the early 1900s. But it was only when Ford optimized production that motor vehicles changed the world.  We see a parallel here.”

Integral to this holistic and efficient approach, Jointechlabs support team will guide and train doctors on best practices. This training covers each of the three phases of microfat-based procedures.

A MiniTC microfat training session.

Best practices training for microfat-based procedures using MiniTC®

“The safety and effectiveness of microfat-based procedures have been shown through years of clinical experience,” said Dr. Nishit Pancholi, COO.  “However, for the first time the business case for microfat-based procedures is overwhelming.  MiniTC-based procedures are effective and rewarding for the patient, the doctor, and the practice. We are thrilled to be on the forefront of regenerative medicine adoption”

The above enhancements are available immediately.

More information at www.jointechlabs.com and www.linkedin.com/company/jointechlabs

Contact:  800-217-0491  info@jointechlabs.com.

MiniTC Adipose System Now Faster, More Convenient, Personalized

MiniTC Adipose Processing System and its components

New syringes and a choice of cannulas will make adipose processing faster and personalized to each physician’s needs.

CHICAGO/April 4, 2023 – Jointechlabs, Inc., a privately held US-based regenerative medicine and therapeutics company, today announced upgraded syringes and cannulas that ship with the acclaimed MiniTC and Mini-Stem Adipose Processing systems.

The syringe upgrade provides faster and more efficient harvesting and precise input into and output from the MiniTC device. Additionally, it is FDA-cleared for lipoaspiration.

The additional cannula (lipoaspirate harvester) allows for faster harvesting, yet preserves the high yield ratio of the MiniTC grafting protocol. This second cannula provides the physician with a choice of cannulas based on personal preference.

“Many physicians have said that MiniTC’s current, Sorenson-style cannula is their choice for adipose harvesting, in particular for fibrous and/or lean adipose tissue,” said Dr. Nathan Katz, Jointechlabs CEO. “But others have told us they prefer a faster cannula that reduces harvesting time. By providing a choice with every MiniTC, physicians can now choose the cannula they prefer for virtually any type of patient body structure.”

Dr. Ariana DeMers, Orthopedic Surgeon at Restore Orthobiologic, says “One of my favorite parts of MiniTC is the harvester. It’s probably the best one on the market.”

This upgrade is effective immediately. Any physician with existing inventory who would like the new syringes and cannula can contact the company at https://jointechlabs.com/contact.

About Jointechlabs

Privately-held Jointechlabs is an emerging worldwide leader in point-of-care regenerative medicine. Jointechlabs enables healthcare practitioners and hospitals to provide safe, cost-effective, non-surgical regenerative medicine therapies at the point-of-care without change in infrastructure.
FDA-cleared MiniTC® for the US market is a stand-alone device for processing autologous fat into regenerative-cell-rich microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-pending Mini-Stem System® prepares Microfat and also extracts Stromal Vascular Fraction.
Pipeline products include stem-cell therapeutics such as Bioprinting and injectable stem cell scaffolding.
More information at www.jointechlabs.com

MDSAP Quality Certification Awarded to Jointechlabs

Medical Device Single Audit Program (MDSAP) certification applies to the United States, Canada, Australia, Brazil, and Japan.

MDSAP Certification for Jointechlabs, Inc.

CHICAGO/March 15, 2023 – Jointechlabs, Inc., a privately held US-based regenerative medicine and therapeutics company, today announced it has been granted an MDSAP certification for its quality management system that satisfies the requirements of multiple regulatory jurisdictions. These jurisdictions include the United States, Canada, Australia, Brazil, and Japan.

The MDSAP allows medical device manufacturers to be audited once for compliance with multiple jurisdictions’ standards and regulatory requirements. The program’s main mission is to “…jointly leverage regulatory resources to manage an efficient, effective, and sustainable single audit program focused on the oversight of medical device manufacturers.”

To earn this certification, Jointechlabs underwent a comprehensive audit by a regulatory body. The company demonstrated that its quality management and manufacturing systems conform to the exacting standards of ISO 13485:2016. ISO 13485:2016 is the most recent and rigorous 13485 standard for medical device manufacturers. The requirements cover quality systems, management, and the entire medical device product journey from conceptualization to implementation. Additionally, customer support, event reporting, continuous improvement, and regular product evaluation are components.

“We are thrilled and honored to earn this MDSAP quality certification,” said Dr. Nishit Pancholi, COO of Jointechlabs. “Quality is a core company value and one of the things that set us apart. Moreover, producing the purest, highest quality biologics allows our customers to achieve the best outcome at the lowest risk.”

The MDSAP certification is not mandatory for medical device manufacturers. There is no publicly available listing of companies who are MDSAP certified. However, companies who earn the certification generally make their status known.

More information from the US F.D.A. is available at https://www.fda.gov/medical-devices/cdrh-international-programs/medical-device-single-audit-program-mdsap

Jointechlabs launches European expansion with new partnerships, grants, and subsidiary

European focus includes a new subsidiary in Austria, a medical research center in partnership with a prominent health center, and development and distribution agreements for Germany, Austria, Switzerland, Italy, Spain, and the Balkans.

CHICAGO, OCT. 20, 2022/PRNewswire/–Jointechlabs, Inc., a Regenerative Medicine Solutions company announced a Vienna-based subsidiary named JointechPlus GmbH. They also announced research, development, and clinical partnerships with Laakirchner Gesundheitszentrum (LGZ), a multispecialty health center in Upper Austria, and Educell, a Slovenian biotech company.  New distribution partners include R.E.N.G. GmbH and Eywa S.r.l., while a new grant has been secured from the Slovenian government.

JointechPlus

“JointechPlus (http://www.jointechplus.at/) allows us to develop and market products for and in cooperation with the European community,” said Dr. Nathan Katz, CEO of Jointechlabs.  “We are thrilled to welcome our European partners and investors in our drive to bring regenerative medicine solutions to Europe and the world,” said Dr. Nishit Pancholi, COO of Jointechlabs.

Research, Development, and Clinical Partnerships

JointechPlus has formed a partnership with LGZ (https://www.lgz.co.at/) to establish a medical research center that will be the hub for regenerative medicine solutions, focusing on orthopedic and wound healing therapeutic biologics.

Mr. Christian F. Albrecht, Managing Director at LGZ, said “Our partnership with JointechPlus allows us to bring advanced regenerative medicine solutions to our patients, while expanding our ability to educate and train medical professionals in this fast-growing field.”

Slovenia-based Educell (https:/www.educell.si/en/) has expertise in adipose-derived stem cells, and an extensive clinical network in the Balkans.  The partnership has secured a grant from the Slovenian government, positioning Jointechlabs and Educell to be the leaders in point-of-care adipose-based solutions in the Balkans.

Distribution Partnerships

The distribution agreements focus on Jointechlabs’ adipose processing systems MiniTC® and Mini-Stem System®.  The R.E.N.G. GmbH agreement covers Germany, Austria, and Switzerland, while the agreement with Eywa S.r.l. covers Italy and Spain.

About Jointechlabs

Headquartered in Chicago, IL, privately-held Jointechlabs is an emerging worldwide leader in regenerative medicine, enabling healthcare practitioners to provide safe, cost-effective, non-surgical regenerative medicine therapies at the point of care without change in infrastructure.

FDA-cleared MiniTC® is a stand-alone device for processing autologous fat into regenerative-cell-rich Microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-pending Mini-Stem System® extracts Microfat and Stromal Vascular Fraction.

The pipeline includes the development of stem-cell-based therapeutics with 3D Bioprinted constructs and injectable stem-cell scaffolding.

More information at www.jointechlabs.com and www.linkedin.com/company/jointechlabs.
Contact: info@jointechlabs.com.

Jointechlabs is Granted Additional Patent for Innovations Using Adipose in Regenerative Medicine Applications

Chicago, Ill, October 3, 2022/ — Jointechlabs, a global leader in point-of-care regenerative medicine, was issued US Patent No. 11,447,748, “Encapsulated Adipose-Derived Stem Cells, Methods for Preparation and Therapeutic Use,” the third utility patent in a family of patents, securing the intellectual property portfolio towards planned development steps.

Jointechlabs’ unique technology is designed to enable health practitioners worldwide to utilize autologous adipose tissue and its derivates (a person’s own fat) for joint pain relief and a wide variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications.

“Innovation is a cornerstone of our success and strategy as a pioneer and leader of the regenerative medicine industry,” said Dr. Nathan Katz, CEO of Jointechlabs. “This patent strengths the IP basis of our therapeutic development leveraging the already commercially available MiniTC® and Mini-Stem System® platform family. Securing a solid IP portfolio demonstrates both our commitment to innovation and our ability to secure patent protection in a way that strengthens our leadership and our competitive advantage.”

This latest patent covers methods and systems of encapsulating mesenchymal stem cells in a three-dimensional biocompatible gel matrix, maintaining the viability and location of the stem cells for an extended period, a significant advantage for therapeutic treatment efficacy as compared to stem cells in suspension.

Jointechlabs has a portfolio of 12 US and foreign patents. The latest patent joins the family that includes US Patent Nos 9,931,445, 9,938,501, and 10,745,666, issued between 2018 and 2020, with 11,447,748 extending coverage through 2032. Other patents have been granted in China, EU, Israel, Japan, and Ukraine.

Dr. Nishit Pancholi, COO of Jointechlabs added “We are gratified to have earned this latest patent, further memorializing our innovation, which continues to be validated by the global marketplace success of our products.”

About Jointechlabs

Headquartered in Chicago, IL, privately-held Jointechlabs is an emerging worldwide leader in point-of-care regenerative medicine, enabling healthcare practitioners and hospitals provide safe, cost-effective, non-surgical regenerative medicine therapies at the point-of-care without change in infrastructure.
FDA-cleared MiniTC® for the US market is a stand-alone device for processing autologous fat into regenerative-cell-rich Microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-pending Mini-Stem System® prepares Microfat and also extracts Stromal Vascular Fraction.
Pipeline products include stem-cell therapeutics such as Bioprinting and injectable stem cell scaffolding.
More information at www.jointechlabs.com and www.linkedin.com/company/jointechlabs.
Contact: info@jointechlabs.com.

###